MYO - Myomo, Inc.
NYSE
->
Healthcare
->
Medical Devices
Boston,
United States
Type: Equity
MYO price evolution
MYO
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $2.38 | |||
| Inventory | $1.8 | |||
| Total current assets | $13.65 | |||
| Long term investments | ||||
| Property, plant & equipment | $0.84 | |||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $14.58 | |||
| Current liabilities | ||||
| Accounts payable | $1.07 | |||
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $5.48 | |||
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $5.59 | |||
| Shareholders' equity | ||||
| Retained earnings | -$96.93 | |||
| Other shareholder equity | $0.08 | |||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $12.24 | |||
| Short term investments | ||||
| Net receivables | $2.38 | $1.9 | $1.96 | $0.92 |
| Inventory | $1.8 | $1.4 | $0.81 | $0.71 |
| Total current assets | $13.65 | $9.22 | $19.19 | $14.45 |
| Long term investments | ||||
| Property, plant & equipment | $0.84 | $0.7 | $0.91 | $0.1 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.26 | |||
| Total investments | ||||
| Total assets | $14.58 | $10.16 | $20.1 | $14.71 |
| Current liabilities | ||||
| Accounts payable | $2.19 | $1.32 | $0.72 | $2.85 |
| Deferred revenue | $0 | |||
| Short long term debt | ||||
| Total current liabilities | $5.48 | $3.6 | $4.28 | $2.87 |
| Long term debt | ||||
| Total noncurrent liabilities | $0.27 | |||
| Total debt | ||||
| Total liabilities | $5.59 | $3.8 | $4.69 | $3.14 |
| Shareholders' equity | ||||
| Retained earnings | -$96.93 | -$88.78 | -$78.06 | -$67.69 |
| Other shareholder equity | $0.08 | $0.04 | -$0.06 | -$0.02 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $9.21 | $7.52 | $3.75 | $4.76 |
| Cost of revenue | ||||
| Gross Profit | $6.95 | $5.33 | $2.3 | $3.1 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $7.9 | $6.44 | $6.19 | $5.54 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.08 | $0.11 | $0.08 | $0.07 |
| Interest expense | $0.08 | $0.11 | $0.14 | $0.04 |
| Net income | ||||
| Net income | -$0.97 | -$1.12 | -$3.84 | -$2.46 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $19.24 | $15.56 | $7.58 | |
| Cost of revenue | ||||
| Gross Profit | $13.18 | $10.25 | $4.98 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $21.41 | $20.93 | $16.09 | |
| Operating income | -$10.5 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.16 | $0.07 | ||
| Interest expense | $0.24 | $0.02 | $0.47 | |
| Net income | ||||
| Net income | -$8.15 | -$10.72 | -$11.56 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $1.61 | -$1.21 | -$3.54 | -$2.03 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $5.16 | $5.36 | $5.36 | $9.71 |
| Effect of exchange rate | $0.01 | -$0.01 | -$0.01 | $0.01 |
| Change in cash and equivalents | $0.13 | -$1.03 | -$1.44 | $1.53 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Net income | -$11.56 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$9.03 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$2.03 | -$0.31 | -$0.33 | -$0.05 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $9.71 | $0.38 | $13.17 | $16.78 |
| Effect of exchange rate | $0.01 | -$0.01 | -$0.01 | -$0 |
| Change in cash and equivalents | $1.53 | -$10.18 | $3.28 | $7.7 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $25.24M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$8.38M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |